GSK’s Arranon Response Rates Likely To Predict Clinical Benefit In Leukemia/Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drug Products Advisory Committee votes for accelerated approval of Arranon for relapsed T-cell leukemia and lymphoma.
You may also be interested in...
GlaxoSmithKline's Arranon Clears FDA For Refractory Leukemia & Lymphoma
FDA approves nelarabine for treatment of twice-refractory T-cell leukemia and lymphoma patients Oct. 28.
GlaxoSmithKline's Arranon Clears FDA For Refractory Leukemia & Lymphoma
FDA approves nelarabine for treatment of twice-refractory T-cell leukemia and lymphoma patients Oct. 28.
Oncologic Committee To Meet Nov. 8 On Accelerated Approval Commitments
Committee to revisit drugs with postmarketing commitments previously reviewed in 2003 and give advice for conduct of confirmatory studies for sponsors with newly approved drugs.